Clinical trial · Observational
Real-World Study of DLBCL With Different Genetic Subtypes
A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes
NCT06026488CI-TRIAL-00083939recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DLBCL - Diffuse Large B Cell Lymphoma | Interdigitating Dendritic Cell Sarcoma | PROBABILISTIC | 0.70 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Other | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All enrolled patients
- description
- All patient who signed the consent form for participation to the study
- interventionNames
- Other: Other
Primary outcomes (1)
- measure
- PFS
- timeFrame
- Baseline up to data cut-off (Up to approximately 9 years)
- description
- Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.
Secondary outcomes (5)
- measure
- ORR
- timeFrame
- End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically-confirmed diffuse large B-cell lymphoma (DLBCL) * Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others * Fully comprehension and signature of the informed consent form (ICF) for participation Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period * Severe mental illness * Patients deemed unsuitable for inclusion by the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.